Listed

TherapeuticsMD, Inc.: Form 10-Q for the period ended Jun 30, 2020

Filed with the SEC on Aug 7, 2020 and accepted by EDGAR at Aug 6, 2020, 18:38 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2020-04-01 to 2020-06-30$10.7mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Revenue6 months2020-01-01 to 2020-06-30$23.0mus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
Cost of revenue3 months2020-04-01 to 2020-06-30$4.4mus-gaap:CostOfGoodsAndServicesSold
Cost of revenue6 months2020-01-01 to 2020-06-30$7.1mus-gaap:CostOfGoodsAndServicesSold
Gross profit3 months2020-04-01 to 2020-06-30$6.3mus-gaap:GrossProfit
Gross profit6 months2020-01-01 to 2020-06-30$15.8mus-gaap:GrossProfit
Research and development3 months2020-04-01 to 2020-06-30$2.7mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2020-01-01 to 2020-06-30$6.0mus-gaap:ResearchAndDevelopmentExpense
Selling, general and administrative3 months2020-04-01 to 2020-06-30$48.3mus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2020-01-01 to 2020-06-30$105.3mus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2020-04-01 to 2020-06-30−$45.0mus-gaap:OperatingIncomeLoss
Operating income6 months2020-01-01 to 2020-06-30−$96.0mus-gaap:OperatingIncomeLoss
Interest expense3 months2020-04-01 to 2020-06-30$7.0mus-gaap:InterestExpense
Interest expense6 months2020-01-01 to 2020-06-30$13.3mus-gaap:InterestExpense
Net income3 months2020-04-01 to 2020-06-30−$52.0mus-gaap:NetIncomeLoss
Net income6 months2020-01-01 to 2020-06-30−$108.8mus-gaap:NetIncomeLoss
Diluted EPS3 months2020-04-01 to 2020-06-30−$0.19us-gaap:EarningsPerShareBasicAndDiluted
Diluted EPS6 months2020-01-01 to 2020-06-30−$0.40us-gaap:EarningsPerShareBasicAndDiluted
Operating cash flow6 months2020-01-01 to 2020-06-30−$95.1mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2020-01-01 to 2020-06-30$25.8kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2020-06-30$113.8mus-gaap:Cash
Current assetsAt period end2020-06-30$148.9mus-gaap:AssetsCurrent
Total assetsAt period end2020-06-30$205.5mus-gaap:Assets
Current liabilitiesAt period end2020-06-30$46.5mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2020-06-30$299.6mus-gaap:Liabilities
Long-term debtAt period end2020-06-30$243.8mus-gaap:LongTermDebtNoncurrent
Shareholders' equityAt period end2020-06-30−$94.1mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001387131-20-007144. Last ingested by Listed: Nov 14, 2026, 19:24 ET. Listed shows no prices and gives no investment advice.